Will increase FDG output and sales forcePharmaceutical manufacturer Syncor of Woodland Hills, CA, struck three deals this month that will expand its presence and customer base in the nuclear medicine industry. The company aims to build the
Will increase FDG output and sales force
Pharmaceutical manufacturer Syncor of Woodland Hills, CA, struck three deals this month that will expand its presence and customer base in the nuclear medicine industry. The company aims to build the largest national FDG production network and make PET imaging more accessible to healthcare providers and consumers.
Syncor will acquire Advanced Isotope, a privately held, Tennessee-based company that has two high-yield FDG cyclotron sites nearing completion in Ft. Lauderdale and Orlando, FL. The Ft. Lauderdale facility is expected to open this week, and the Orlando facility is expected to open by August.
Syncor compounds and dispenses radiopharmaceuticals such as fluorine-18 fluorodeoxyglucoseFDGthe radiopharmaceutical used most commonly in PET imaging. FDG is tagged with fluorine-18, a radioisotope that is produced by PET cyclotrons, such as those of Advanced Isotope. Because of the short life of radioisotopes, production facilities must be near the imaging facility where it will be used.
Kent Simpkins, president and CEO of Advanced Isotope, said the financial strength of Syncor will be coupled with his companys strong management team.
Syncors second deal is a strategic relationship with GE Medical Systems and builds on the Advanced Isotope acquisition. Under the agreement, GE salespeople will be able to offer Syncors FDG radiopharmaceuticals when they are selling the GE Advance PET scanner to customers, said Tim Guttman, Syncors financial controller.
Syncor will buy several of GEs Advance PET scanners and PET trace cyclotrons. The facilities Syncor is gaining through the Advanced Isotope acquisition are already equipped with GE Advance PET scanners.
Officials at both companies said the agreement will make PET technology more accessible. In addition, Syncor and GE Medical will collaborate on an e-commerce business plan that links their Web sites.
The third deal is a new partnership under which Syncor and Ion Beam Applications will soon begin construction on new FDG manufacturing facilities. Installations in Newark, N.J., and Philadelphia are slated to open in the first half of 2001, while others in New Orleans and Detroit will open at the end of 2001.
The two companies will announce the locations of more domestic centers in the next few months and start construction on international sites within the next year.
Under the agreement, IBA will provide the radioisotope-producing equipment while Syncor provides the services to dispense, package, and deliver PET unit doses.
Could Virtual Non-Contrast Images from Photon-Counting CT Reduce Radiation Dosing with CCTA?
March 28th 2024Emerging research on coronary artery calcium scoring for the assessment of coronary artery disease (CAD) suggests the use of virtual non-contrast images from photon-counting CT may lead to a nearly 20 percent reduction in radiation dosing.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Mobile C-Arm Device that May Accelerate Fluoroscopic and 3D CT Imaging
March 21st 2024Offering ease of mobility and self-driving capabilities, the Ciartic Move C-arm device reportedly reduces the stress and potential for error associated with manual repositioning during intraoperative imaging with computed tomography and fluoroscopy.